A Revolutionary Approach to Fighting Heart Disease: Gene Editing for High Cholesterol

The Dawn of a New Treatment Era

In what could mark a turning point in cardiovascular medicine, scientists are exploring an innovative approach to combat heart disease through gene-editing technology. Rather than relying on daily medication, this groundbreaking treatment aims to provide a one-time solution for managing high cholesterol. While still in its early stages and tested on only a few dozen individuals, the preliminary results have generated considerable excitement in the medical community. Two companies developing different gene-editing approaches have demonstrated that by switching off specific genes, they can dramatically reduce artery-clogging cholesterol levels, potentially preventing heart attacks without the need for lifelong pill-taking. Dr. Luke Laffin, a preventive cardiologist at the Cleveland Clinic who co-authored a promising study published in the prestigious New England Journal of Medicine, captures the sentiment perfectly: “People want a fix, not a bandage.” The overwhelming interest he received from people eager to participate in future clinical trials underscores the public’s hunger for more permanent solutions to this widespread health challenge.

Understanding the Cholesterol Problem

To appreciate the significance of this breakthrough, it’s important to understand the role cholesterol plays in our health and why it poses such a significant threat. While cholesterol is essential for various bodily functions, excessive amounts—particularly LDL cholesterol, often called “bad” cholesterol—accumulate as plaque in artery walls, becoming a primary driver of heart attacks and strokes. Cardiovascular disease remains the leading cause of death both in the United States and globally, affecting millions of lives each year. Currently, millions of people take cholesterol-lowering medications like statins, which serve as the cornerstone of treatment. However, many patients continue to struggle with bringing their cholesterol to safe levels, and maintaining a medication regimen for life presents significant challenges. Many people discontinue their medications due to unpleasant side effects or simply the difficulty of remembering daily pills for decades. According to the American Heart Association, while diet plays a role in cholesterol levels, the liver produces most of the cholesterol our bodies need, and our genes significantly influence how it’s managed. This genetic component has proven to be both the problem and, potentially, the solution.

The Genetic Discovery That Changed Everything

The path to this potential breakthrough began with observing nature’s own experiments. Some individuals inherit genes that trigger dangerously high cholesterol levels, while others possess naturally extremely low cholesterol throughout their lives and rarely develop heart disease. Years ago, Dr. Kiran Musunuru, now a cardiologist at the University of Pennsylvania, made a fascinating discovery about these fortunate individuals. He reported that some people with naturally low cholesterol harbor a mutation that effectively turns off a gene called ANGPTL3, which lowers their levels of both LDL cholesterol and triglycerides, another harmful fat. Separately, geneticists at UT Southwestern Medical Center identified other individuals whose extremely low LDL resulted from the loss of function in a different gene named PCSK9. These natural genetic variations essentially provided scientists with a roadmap. As noted by Dr. Steven Nissen of the Cleveland Clinic, who oversaw an ANGPTL3 study funded by Swiss-based CRISPR Therapeutics, “It’s a natural experiment in what would happen if we actually changed the gene.” These discoveries revealed that people with these naturally nonfunctioning genes experienced no apparent negative consequences—they simply enjoyed the benefit of protection against heart disease. This observation provided the foundation for developing treatments that could artificially replicate these protective genetic mutations in people at high risk for cardiovascular disease.

How the New Treatment Works

The current research utilizes CRISPR, the Nobel Prize-winning gene-editing technology, to attempt switching off one of these cholesterol-regulating genes in people facing high risk from uncontrolled cholesterol. While injected medicines already exist that block the proteins produced by the PCSK9 and ANGPTL3 genes in the liver, this new approach goes a step further by editing the genes themselves. In one groundbreaking study, fifteen adults received a single infusion of microscopic particles carrying the CRISPR editing tool directly to the liver, where it switched off the ANGPTL3 gene inside the organ’s cells. The results were dramatic: within just two weeks, participants receiving the highest dose experienced a fifty percent reduction in both their LDL and triglyceride levels, as reported by Drs. Laffin and Nissen in November. Similarly impressive results came from Verve Therapeutics, a subsidiary of pharmaceutical giant Eli Lilly based in Boston, which reported that its PCSK9-targeted editing infusion achieved comparable LDL cholesterol reduction in a small study. Both companies conducted their initial studies in Australia, the United Kingdom, and other countries, with U.S. study sites now beginning to open. The gene-editing approach is considered permanent because if the edited liver cells reproduce, their offspring contain the altered genes. According to Dr. Musunuru, who co-founded Verve, the edits have lasted a lifetime in mice, and some participants in an earlier Verve study have been tracked for two years with their cholesterol still lowered.

Safety Concerns and Future Research Needs

Despite the encouraging preliminary results, significant questions remain about the long-term safety and efficacy of this approach. Dr. Joseph Wu of Stanford University, who wasn’t involved in either study, emphasizes that CRISPR-based therapies for any disease haven’t been used extensively enough to establish long-term safety profiles. Specific concerns include the potential for the particles carrying the gene-editing tool to irritate or inflame the liver. Additionally, scientists cannot yet guarantee that gene editing hits only the intended target—unintended edits to other genes could potentially cause unforeseen health problems down the line. These safety considerations explain why current studies largely target people at very high risk from cardiovascular disease, where the potential benefits clearly outweigh the unknown risks. Longer studies involving far more participants are essential before this treatment could become widely available. While people with naturally nonfunctioning ANGPTL3 or PCSK9 genes have shown no apparent negative consequences, replicating this condition artificially through gene editing may present different challenges. The medical community must proceed carefully and methodically to ensure that this promising treatment doesn’t create new problems while solving an old one.

What You Can Do Right Now for Heart Health

Whether gene editing eventually proves successful or not, the American Heart Association emphasizes that there are eight key factors for better heart health that everyone should address immediately. Several involve lifestyle modifications that can significantly impact cardiovascular health. First, adopt a heart-healthy diet rich in fruits and vegetables, whole grains, and healthy fats like those found in nuts. Saturated fats can increase cholesterol, while healthier dietary choices can lower LDL levels and raise HDL, the beneficial “good” cholesterol. Regular physical activity is crucial, as exercise can increase good HDL cholesterol and help lower triglycerides. Maintaining a healthy weight, quitting smoking if you’re a smoker, and getting adequate sleep all contribute to heart health. On the medical side, controlling blood pressure is essential—levels measuring less than 120 over 80 are considered optimal. Since diabetes also damages the heart, controlling blood sugar is equally important. Regarding cholesterol specifically, keeping LDL levels at 100 is generally acceptable for healthy individuals, but once people develop high cholesterol or heart disease, guidelines recommend lowering it to at least 70, or even lower for those at very high risk. When lifestyle changes prove insufficient, statin medications like Lipitor, Crestor, or their affordable generic equivalents can effectively block some of the liver’s cholesterol production. Additional pill options exist for people who need extra help or cannot tolerate statins, along with some injected medicines. While we await the promise of gene-editing treatments, these proven interventions remain our best tools for protecting our hearts and extending our lives.